DOI : 10.1055/s-00000054

Pharmacopsychiatry

Issue 05 · Volume 36 · September 2003 DOI: 10.1055/s-002-2876


23. Symposium of the AGNP
Munich, October 8th–10th, 2003

Prof. Dr. J.B.Aldenhoff

1
Ackl, N.; Schreiber, Y. A.; Ising, M.; Sonntag, A.; Auer, D. P.: Evaluation of 1H-MRS as diagnostic marker for mild cognitive impairment and dementia
2
Adena, S. M.; Ising, M.; Lauer, C.; Holsboer, F.; Modell, S.: The effects of RS-86 on sleep with respect to depression and HLA-type
3
Adli, M.; Stamm, T.; Kirchheiner, J.; Tremblay, P.; Smolka, M.; Kießlinger, U.; Bauer, M.: Serotonin transporter gene polymorphism and response to lithium augmentation in patients with treatment-refractory depression
5
Albrecht, N.; Hornung, O. P.; Regen, F.; Danker-Hopfe, H.; Schreqdl, M.; Heuser, I.: The significance of non-REM sleep for memory processes in elderly subjects
7
Angst, J.; Gamma, A.; Stassen, H. H.; Ajdacic, V.; Eich, D.; Rössler, W.: A longitudinal syndrome-oriented approach to phenotypic heterogeneity
10
Baghai, T. C.; Schüle, C.; Eser, D.; Zwanzger, P.; Ella, R.; Deiml, T.; Zill, P.; Rupprecht, R.; Bondy, B.: Gender influence on pharmacogenetic prediction of antidepressive efficacy
13
Bartels, M.; Kastrup, A.; Schlotter, W.; Plewnia, C.: Treatment of tics in Tourette’s syndrome with aripiprazole
14
Bauer, M.; London, E. D.; Rasgon, N.; Berman, S. M.; Frye, M. A.; Mazziotta, J. C.; Altshuler, L.; Whybrow, P. C.: Supraphysiological doses of L-thyroxine alter regional cerebral metabolism in refractory bipolar depression: A FDG-PET study
15
Baumann, B.; Bielau, H.; Bogerts, B.; Bernstein, H. G.: Effects of antidepressants in postmortem and neuroimaging studies
17
Baumann, P.; Hiemke, C.; Ulrich, S.; Gaertner, I.; Rao, M. L.; Eckermann, G.; Gerlach, M.; Kuss, H. J.; Laux, G.; Müller-Oerlinghausen, B.; Riederer, P.; Zernig, G.: Presentation of the AGNP-TDM expert group consensus guideline on „Therapeutic Monitoring of Psychotropic Drugs“
19
24
Bernhardt, K.; Friege, L.; Gerok-Falke, K.; Röhling, K.; Aldenhoff, J. B.: A new concept for crisis management in borderline patients
28
Bokde, A. L. W.; Lopez-Bayo, P.; Teipel, S. J.; Dong, W.; Pechler, S.; Leinsinger, G.; Born, C.; Fuchsberger, T.; Faltraco, F.; Möller, H. J.; Hampel, H.: Neural representation of cognitive changes within the visual system in the AD brain
31
Brettschneider, S.; Morgenthaler, N.; Teipel, S. J.; Fischer-Schulz, C.; Bürger, K.; Möller, H. J.; Bergmann, A.; Hampel, H.: Decrease of amyloid β1–42 antibodies in serum of patients with Alzheimer's disease
32
Brunner, J.; Bronisch, T.; Pfister, H.; Jacobi, F.; Wittchen, H. U.: High cholesterol, triglycerides, and body-mass index in suicide attempters with major depression
33
Brunner, J.; Ising, M.; Binder, E. B.; Künzel, H. E.; Nickel, T.; Pfennig, A.; Kern, N.; Fuchs, B.; Majer, M.; Holsboer, F.; Modell, S.: Prediction of response to antidepressant monotherapy
34
Bschor, T.; Ising, M.; Bauer, M.; Lewitzka, U.; Skerstupeit, M.; Müller-Oerlinghausen, B.; Baethge, C.: Time in depression and mania: Running fast or running slow? A computer based, controlled study of 93 depressed, manic and control subjects
37
Cohrs, S.; Rodenbeck, A.; Guan, Z.; Pohlmann, K.; Jordan, W.; Meier, A.; Rüther, E.: Cortisol-reducing properties of quetiapine in healthy subjects under an undisturbed and an acoustic stress condition
38
Cohrs, S.; Rodenbeck, A.; Guan, Z.; Pohlmann, K.; Jordan, W.; Meier, A.; Rüther, E.: Quetiapine improves sleep quality in healthy subjects
39
Colla, M.; Deuschle, M.; Meichel, K.; Hagen, T.; Kronenberg, G.; Heuser, I.: Hippocampal volume reduction and HPA-system activity in major depression
40
Cordes, J.; Kostorz, L.; Henning, U.; Schillen, T.; Burtscheidt, W.; Kirschbaum, C.; Klimke, A.: Electronic monitoring of the cortisol daytime profiles during the process of alcohol withdrawal
41
Czisch, M.; Wehrle, R.; Kaufmann, C.; Wetter, T. C.; Holsboer, F.; Pollmächer, T.; Auer, D. P.: Thalamo-cortical synchronization across the sleep-wake cycle: A combined fMRI/EEG study
43
Dames, P.; Dong-Si, T.; Dahmen, N.; Giegling, I.; Hartmann, A. M.; Möller, H. J.; Rujescu, D.: Association study between the mitochondrial citrate transporter gene, a positional candidate on chromosome 22q, and schizophrenia
44
Danos, P.; Bernstein, H. G.; Krell, D.; Stauch, R.; Falkai, P.; Bogerts, B.: The medial geniculate nucleus and schizophrenia: A volumetric post-mortem study
45
Daumann, J.; Schnitker, R.; Thron, A.; Gouzoulis-Mayfrank, E.: Neural correlates of working memory in pure and polyvalent ecstasy (MDMA) users
46
Degner, D.; Bandelow, B.; Akkan, R.; Kropp, S.; Nietmann, P. D.; Rüther, E.; Bleich, S.: Relevance of therapeutic drug monitoring (TDM) in patients with quetiapine administration
47
Deiml, T.; Haseneder, R.; Zieglgänsberger, W.; Baghai, T. C.; Eser, D.; Schüle, C.; Ella, R.; Eisensamer, B.; Rupprecht, R.; Hapfelmeier, G.: α-thujone reduces 5-HT3 receptor activity by an effect on the agonist-induced desensitization
50
Dettling, M.; Urbanek, C.; Mossiaguine, I.; Roots, I.; Müller-Oerlinghausen, B.; Cascorbi, I.: The role of myeloperoxidase and NADPH oxidase polymorphisms in clozapine-induced agranulocytosis
54
Deussing, J.; Breu, J.; Binder, E. B.; Ohl, F.; Holsboer, F.; Wurst, W.: Addressing in vivo functions of urocortin III, a novel member of the CRH family of neuropeptides
55
Dielentheis, T. F.; Schreckenberger, M.; Lochmann, M.; Lange-Asschenfeld, C.; Siessmeier, T.; Buchholz, H. G.; Hobusch, K.; Hirsch, J.; Vernaleken, I.; Mann, K.; Bartenstein, P.; Gründer, G.: Sensitivity of GABAergic systems in male alcoholics and subjects at risk for alcoholism
56
57
58
Dragicevic, A.; Müller, M. J.; Sachse, J.; Härtter, S.; Hiemke, C.: Therapeutic drug monitoring (TDM) of quetiapine
60
Ebinger, M.; Grauer, M. T.; Weiser, C.; Rickel, S.; Franc, D.; Uhr, M.: Results of routine CSF analysis of 1000 psychiatric patients
62
Ehrenreich, H.; Sirén, A. L.: Neuroprotection in neuropsychiatric disease
63
Eichhammer, P.; Langguth, B.; Zowe, M.; Hajak, G.: Cortical excitability in neuroleptic-naive first-episode schizophrenic patients
64
Eichhammer, P.; Laufkötter, R.; Langguth, B.; Frank, E.; Hajak, G.: Cortical excitability in patients with adult ADHD
65
Eichler, O.; Block, W.; Träber, F.; Schildberg, F.; Bopp, G.; Warnecke, M.; Wagner, M.; Schild, H.; Maier, W.; Schütz, C. G.: Brain plasticity, cognitive functioning and the relationship to treatment outcome in patients with tobacco dependence
66
Eisensamer, B.; Rammes, G.; Gimpl, G.; Shapa, M.; Ferrari, U.; Hapfelmeier, G.; Bondy, B.; Parsons, C.; Gilling, K.; Zieglgänsberger, W.; Holsboer, F.; Rupprecht, R.: Antidepressants are functional antagonists at the serotonin type 3 (5-HT3) receptor
67
Ella, R.; Marocco, J.; Weyh, T.; Zwanzger, P.; Wendicke, K.; Baghai, T. C.; Schüle, C.; Deiml, T.; Rupprecht, R.; Möller, H. J.; Padberg, F.: Evaluation of a novel sham condition for repetitive transcranial magnetic stimulation (rTMS)
70
Eser, D.; Zwanzger, P.; Aicher, S.; Schüle, C.; Baghai, T. C.; Padberg, F.; Ella, R.; Möller, H. J.; Rupprecht, R.: Effects of alprazolam on cholecystokinin-tetrapeptide (CCK-4) induced panic and hypothalamic-pituitary-adrenal (HPA) axis activity
73
Fehr, C.; Tadic, A.; Schmidt, L. G.; Sander, T.; Lenzen, K.; Nuernberger, P.; Anghelescu, I.; Szegedi, A.: From mouse models to human behavior: Testing candidate genes for alcoholism
74
Fehsel, K.; Loeffler, S.; Henning, U.; Kronenwett, R.; Krieger, K.; Klimke, A.: Increased sensitivity of isolated CD34+ cells towards clozapine-treatment
75
Fellgiebel, A.; Sachse, J.; Schmidt, L. G.; Hiemke, C.: Therapeutic drug monitoring (TDM) of donepezil
76
Fischer-Barnicol, D.; Lanquillon, S.; Reischle, E.; Haen, E.; Hajak, G.; Klein, H. E.: Perazine – the atypical side of an conventional antipsychotic
77
Forlenza, O. V.; Mendes, C. T.; Schaeffer, E. L.; Gattaz, W. F.: Phospholipase a2 activity in rat embryonic brain and in primary cultures of cortical neurons
79
Frodl, T.; Zetzsche, T.; Höhne, T.; Banac, S.; Schorr, C.; Jäger, M.; Leinsinger, G.; Bottlender, R.; Reiser, M.; Möller, H. J.; Meisenzahl, E. M.: Structural changes of the hippocampus and the amygdala in patients with major depression and healthy controls during a one year follow-up
81
Gallinat, J.; Bajbouj, M.; Sander, T.; Xu, K.; Goldman, D.; Winterer, G.: Association of the G1947A COMT (Val108/158Met) gene polymorphism with prefrontal P300 during information processing
82
Gattaz, W. F.; Forlenza, O. V.; Talib, L. L.; Barbosa, N. R.; Bottino, C. M. C.: Decreased platelet phospholipase A2 activity in Alzheimer's disease and mild cognitive Impairment
83
Gattaz, W. F.; Wacker, P.; Nunes, P. V.; Bottino, C. M. C.; Castro, C. C.; Cerri, G. G.; Forlenza, O. V.: Abnormal phospholipid metabolism in Alzheimer's disease: 31P-spectroscopy study of the pre-frontal cortex
86
Giegling, I.; Engel, R. R.; Möller, H. J.; Rujescu, D.: Systematic screen of serotonergic genes in suicidal behaviour
87
Giesler, M.; Rocamora, R.; Haag, A.; Becker, A.; Thum, A.; Krieg, J. C.; Hemmeter, U.: Polysomnographic evaluation of patients with different types of dementia and treatment with cholinsterase Inhibitors, first results
88
Glatz, D.; Berendt, F.; Faltraco, F.; Hartmann, A. M.; Hampel, H.; Möller, H. J.; Riederer, P.; Rujescu, D.: Altered expression of tau exon 10, clk2 and htra2-ß in post mortem brain of patients with Alzheimer’s disease
89
Göder, R.; Boigs, M.; Braun, S.; Friege, L.; Fritzer, G.; Aldenhoff, J. B.; Hinze-Selch, D.: Modulation of sleep: A new approach of treating memory impairment in schizophrenia?
90
Göder, R.; Fritzer, G.; Boigs, M.; Braun, S.; Aldenhoff, J. B.; Hinze-Selch, D.: Sleep-EEG in patients with schizophrenia: Analysis of power spectra and dimensional complexity
96
Gründer, G.; Schreckenberger, M.; Dielentheis, T. F.; Lochmann, M.; Mann, K.; Lange-Asschenfeld, C.; Siessmeier, T.; Buchholz, H. G.; Amberg, R.; Bartenstein, P.: Effects of alcohol and benzodiazepines on brain metabolism: [18F]FDG-PET studies
97
Gründer, G.; Vernaleken, I.; Siessmeier, T.; Buchholz, H. G.; Heinz, A.; Gjedde, A.; Cumming, P.; Bartenstein, P.: Pharmacological modulation of dopaminergic systems in neuropsychiatric disorders studied with positron emission tomography
99
102
Hajak, G.; Eichhammer, P.; Langguth, B.: High-frequency transcranial magnetic stimulation in schizophrenia
103
Hajak, G.; Johann, M.; Langguth, B.; Wodarz, N.; Eichhammer, P.: High-frequency transcranial magnetic stimulation decreases cigarette smoking
104
106
Hanewald, B.; Franz, M.; Gruppe, H.; Gallhofer, B.: Subjective reactions to neuroleptic treatment: Prediction of compliance?
107
Hanisch, M.; Lis, S.; Cetin, T.; Gallhofer, B.; Krieger, S.: Multiple T-mazes in the analysis of visuo-motor interactions in schizophrenia
108
Hartmann, A. M.; Giegling, I.; Beissbarth, T.; Dames, P.; Rujescu, D.: cDNA arrays analyses in an animal model for psychosis-related traits
109
Hatzinger, M.; Brand, S.; Hemmeter, U.; Annen, B.; Holsboer-Trachsler, E.: Predictive value of sleep EEG markers in long-term course of depression
111
Held, K.; Mathias, S.; Schüssler, P.; Weikel, J. C.; Steiger, A.: GHRH impairs sleep in normal females
113
Hemmeter, U.; Thum, A.; Hamark, L.; Bäcker, A.; Rocamora, R.; Penzel, T.; Krieg, J. C.: Actigraphy in patients with depression and schizophrenia concerning activity levels, sleep estimation and circadian rhythm
118
Heres, S.; Leucht, S.; Hamann, J.; Kissling, W.: Language Bias in Neuroscience – Is the Tower of Babel located in Germany?
119
Herr, A. S.; Tsolakidou, A.; Yassouridis, A.; Holsboer, F.; Rein, T.: Antidepressants differentially influence the transcriptional activity of the glucocorticoid receptor in vitro
120
Hetzel, G.; Moeller, O.; Erfurth, A.; Michael, N.; Rothermundt, M.; Arolt, V.; Evers, S.: The impact of reboxetine and citalopram on visually-evoked event-related potentials in depressed patients
121
Hetzel, G.; Moeller, O.; Evers, S.; Michael, N.; Rothermundt, M.; Arolt, V.; Erfurth, A.: Visually-evoked event-related potentials and oral citalopram challenge test
122
Hiemke, C.; Sachse, J.; Dragicevic, A.; Härtter, S.: Costs and effectiveness of therapeutic drug monitoring in psychiatry
123
Hillemacher, T.; Bayerlein, K.; Kromolan, B.; Sperling, W.; Kornhuber, J.; Bleich, S.: Craving differs with alcoholic beverages
126
127
Himmerich, H.; Schuld, A.; Haack, M.; Kaufmann, C.; Pollmächer, T.: Early prediction of changes in weight during six weeks of treatment with antidepressants
129
Hinze-Selch, D.; Samadi, P.; Kell, S.; Petersen, I.: Effect of antipsychotics on microglia in vitro
131
Hornung, O. P.; Albrecht, N.; Regen, F.; Danker-Hopfe, H.; Schredl, M.; Heuser, I.: Does REM-sleep manipulation have a differential effect on learning and memory in healthy older adults?
133
Huebner-Liebermann, B.; Zwisler, R.; Spießl, H.; Klein, H. E.: Antidepressants from an internet-patients’ viewpoint
134
Ibach, B.; Kerchlango, A.; Haen, E.; Klein, H. E.: Psychopharmacotherapy and adverse drug effects in old age psychiatry
135
Impler, E. M.; Dahmen, N.; Giegling, I.; Hartmann, A. M.; Möller, H. J.; Rujescu, D.: Association study of SNPs in G72 and DAAO in schizophrenia
136
Ising, M.; Adena, S. M.; Pfennig, A.; Binder, E. B.; Kern, N.; Huber, J.; Modell, S.; Holsboer, F.: Munich Vulnerability Study – Familial vulnerability for affective disorders: Search for endophenotypes
137
Ising, M.; Binder, E.; Brunner, J.; Fuchs, B.; Kern, N.; Künzel, H. E.; Majer, M.; Nickel, T.; Pfennig, A.; Modell, S.; Holsboer, F.: Subsyndromal AMDP scales to distinguish pathogenetically homogenous subgroups of affective disorders
139
Jockers-Scherübl, M. C.; Bauer, A.; Godemann, F.; Reischies, F. M.; Selig, F.; Schlattmann, P.: Negative symptoms of schizophrenia are improved by the addition of paroxetine to neuroleptics: A double-blind placebo-controlled study
140
Jockers-Scherübl, M. C.; Matthies, U.; Danker-Hopfe, H.; Selig, F.; Mahlberg, R.; Lang, U. E.; Hellweg, R.: Cannabis and multiple substance abuse raise the serum concentrations of the neurotrophins NGF and BDNF in drug-naïve schizophrenic patients
141
Jordan, W.; Berger, C.; Cohrs, S.; Rodenbeck, A.; Mayer, G.; Niedmann, P.; Rüther, E.; Bleich, S.: Serum homocysteine in obstructive sleep apnea syndrome can be lowered by CPAP-therapy
142
Jordan, W.; Reinbacher, A.; Cohrs, S.; Grunewald, R. W.; Mayer, G.; Rüther, E.; Rodenbeck, A.: Circulating big endothelin-1 is disproportionately elevated in obstructive sleep apnea
145
Karow, A.; Ritzhaupt, A.; Roesch, F.; Novick, D.; Naber, D.; Dittmann, R. W.: Association of clinical and non-clinical factors with subjective well-being – data of the SOHO study
146
Keck, M. E.; Welt, T.; Müller, M. B.; Landgraf, R.; Holsboer, F.: Modulation of CRH and AVP as a therapeutic strategy in anxiety disorders
147
Keil, U.; Steiner, B.; Haass, C.; Müller, W. E.; Eckert, A.: Amyloid beta induces mitochondrial dysfunction in a dose-dependent manner
148
Kern, N.; Binder, E. B.; Künzel, H. E.; Pfennig, A.; Fuchs, B.; Ising, M.; Erhardt, A.; Lucae, S.; Müller-Myhsok, B.; Modell, S.; Keck, M. E.; Holsboer, F.: Is there a genetic continuum between anxiety and depression?
149
Kiefer, F.; Jahn, H.; Wolf, K.; Raedler, T.; Wiedemann, K.: Gender effects in pharmacological relapse prevention of alcoholism
150
Kircher, T.; Erb, M.; Grodd, W.; Leube, D.: Pharmako-FMRT in Alzheimers dementia
152
Kirner, A.; Meisenzahl, E. M.; Giegling, I.; Leinsinger, G.; Reiser, M.; Möller, H. J.; Rujescu, D.: Methionine homozygosity at codon 129 in the prion protein is associated with white matter reduction and enlargement of CSF compartments
156
159
Kraus, T.; Bayerlein, K.; Reulbach, U.; Bleich, S.: Leptin plasma levels and craving data during alcohol withdrawal
163
Krömer, S. A.; Milfay, D.; Wigger, A.; Jacob, W.; Keßler, M.; Bunck, M.; Zimbelmann, M.; Birg, I. N.; Landgraf, R.; Turck, C. W.: Validation of a genetic mouse model for anxiety and comorbid depression
164
Kuhn, H. G.: Adult neurogenesis
165
Kungel, M.; Ebrecht, M.; Modell, S.; Wagner, P.; Carson, W.; Marcus, R.: Efficacy and tolerability of aripiprazole compared to perphenazine in treatment-resistant schizophrenia
166
Laakmann, G.; Hennig, J.; Baghai, T. C.; Schüle, C.: Influence of mirtazapine on salivary cortisol in depressed patients
167
168
Lanquillon, S.; Fischer-Barnicol, D.; Haen, E.; Hajak, G.; Klein, H. E.: Benefit of modern antipsychotics still withheld from forensic patients
172
Lieb, K.; Herpfer, I.; Fiebich, B. L.; Berger, M.: Modulation of neuropeptidergic circuits
176
Loeffler, S.; Fehsel, K.; Krieger, K.; Henning, U.; Klimke, A.: In vitro, inhibition of oxidative stress prevents clozapine-induced apoptosis in neutrophils
179
Lutz, B.; Monory, K.; Hermann, H.; Cannich, A.; Kamprath, K.; Wotjak, C. T.; Marsicano, G.: The roles of the endogenous cannabinoid system in learning and memory in mice
183
Marques, C. A.; Keil, U.; Bonert, A.; Steiner, B.; Haass, C.; Müller, W. E.; Eckert, A.: Neurotoxic mechanisms triggered by ß-amyloid: Role of oxidative stress, caspases and JNK pathway
185
Meisenzahl, E. M.; Frodl, T.; Schmitt, G. J. E.; Zetzsche, T.; Dresel, S.; LaFougere, G.; Hahn, K.; Möller, H. J.: Combined dopamine transporter and D2-receptor imaging in schizophrenia: Implications for atypical neuroleptics
186
Mergl, R.; Henkel, V.; Gallinat, J.; Kotter, G.; Müller-Siecheneder, F.; Pogarell, O.; Juckel, G.; Schröter, A.; Bürger, K.; Hampel, H.; Bahra, R.; Emir, B.; Laux, G.; Möller, H. J.; Hegerl, U.: Kinematical analysis of the effects of donepezil hydrochloride on hand motor function in patients with Alzheimer's dementia*
187
Mergl, R.; Mavrogiorgou, P.; Juckel, G.; Pogarell, O.; Göbel, C.; Zaudig, M.; Hauke, W.; Hegerl, U.: Effects of sertraline on kinematical aspects of hand movements in patients with obsessive-compulsive disorder*
188
189
Modell, S.; Ebrecht, M.; Kungel, M.; Wagner, P.; Marcus, R.; Carson, W.: Long-term treatment with aripiprazole and its effects on negative and affective symptoms of schizophrenia
190
Modell, S.; Kungel, M.; Ebrecht, M.; Wagner, P.; Marcus, R.; Carson, W.: Efficacy of aripiprazole in the treatment of mania
191
Moeller, O.; Hetzel, G.; Michael, N.; Arolt, V.; Erfurth, A.: High basal prolactin values predict response to reboxetine treatment in major depression
193
196
Müller, M. B.; Zimmermann, S.; Sillaber, I.; Hagemeyer, T. P.; Deussing, J.; Droste, S.; Reul, J. H. M. H.; Holsboer, F.; Wurst, W.: Limbic Crhr1 mediates anxiety-related behaviour and is required for hormonal adaptation to stress
197
Müller, M. J.; Herr, R.; Maurer, C.; Müller, K. M.; Schmidt, L. G.: Attitudes towards different drug formulations in patients and staff members of a psychiatric hospital
198
Müller, M. J.; Regenbogen, B.; Sachse, J.; Härtter, S.; Hiemke, C.: Naturalistic treatment of positive symptoms in schizophrenia with amisulpride: Are there gender differences?
203
204
Murgatroyd, C.; Wigger, A.; Spengler, D.; Landgraf, R.: Molecular-genetic dissection of anxiety/depression: From HAB phenotype to functional SNP
206
Netter, P.; Toll, C.; Lujic, C.; Siegmund, A.; Birkenbach-Holdschuh, T.; Reuter, M.; Hennig, J.: A new measure of the dopamine challenge by bromocriptine for testing personality
207
Neuhaus, A. H.; Gallinat, J.; Bajbouj, M.; Reischies, F. M.: EEG source localization during postictal delirium following electroconvulsive therapy
211
Oehl, M. A.; Hummer, M.; Baumgartner, S.; Ebenbichler, C.; Edlinger, M.; Hofer, A.; Kemmler, G.; Lechleitner, M.; Fleischhacker, W. W.: Alterations of glucose metabolism under treatment with atypical antipsychotics
212
Ohl, F.; Binder, E. B.; Rödel, A.; Weißenbacher, P.; Keck, M. E.: ENU-mouse mutagenesis screen: In search of animal models of psychiatric disorders
213
Otte, C.; Lenoci, M.; Metzler, T. J.; Yehuda, R.; Marmar, C. R.; Neylan, T. C.: Increased 24-hour urinary cortisol and decreased endocrine and sleep response to metyrapone in posttraumatic stress disorder
214
Pfennig, A.; Kuenzel, H. E.; Kern, N.; Fuchs, B.; Brunner, J.; Ising, M.; Modell, S.; Müller-Myhsok, B.; Binder, E. B.; Holsboer, F.: HPA axis dysregulation and suicidal behavior in depression – Differentiation of a genetically distinct subgroup?
216
Pogarell, O.; Ella, R.; Jakob, F.; Baghai, T. C.; Mulert, C.; Koch, W.; Pöpperl, G.; Tatsch, K.; Rupprecht, R.; Möller, H. J.; Hegerl, U.; Padberg, F.: Neurobiological effects of TMS: Functional neuroimaging of dopaminergic neurotransmission using SPECT and [123I] IBZM
217
Pogarell, O.; Juckel, G.; Tatsch, K.; Norra, C.; Müller-Siecheneder, F.; Mulert, C.; Folkerts, M.; Frodl, T.; Hegerl, U.: Auditory Evoked Potentials and 123I-β-CIT-SPECT as predictors of the differential response to serotonergic versus noradrenergic antidepressants
218
Pogarell, O.; Müller-Siecheneder, F.; Mulert, C.; Folkerts, M.; Frodl, T.; Juckel, G.; Hegerl, U.: Effects of citalopram and reboxetine on the loudness dependence of auditory evoked potentials in patients with major depression
219
Pogarell, O.; Schulz, C.; Müller-Siecheneder, F.; Juckel, G.; Frodl, T.; Mergl, R.; Laux, G.; Möller, H. J.; Hegerl, U.: Auditory evoked P300 and treatment response to donepezil versus placebo in patients with Alzheimer’s disease
220
Putzhammer, A.; Pfeiff, L.; Perfahl, M.; Heindl, B.; Hajak, G.; Klein, H. E.: Ultrasonic gait analysis: Differentiation of effects of schizophrenia and of antipsychotic treatment
223
Raedler, T.; Jahn, H.; Goedecken, B.; Gescher, D.; Kellner, M.; Wiedemann, K.: Megestrol attenuates hormonal response to CCK-4
224
226
Reiff, J.; Witt, K.; Daniels, C.; Volkmann, J.; Deuschl, G.; Aldenhoff, J. B.: Comparative study of citalopram and amitriptyline in depression in patients with Parkinson’s disease
227
Rein, T.; Wochnik, G. M.; Schmidt, U.; Rosenhagen, M.; Holsboer, F.: Role of chaperones in signal transduction of the glucocorticoid receptor
230
233
Rosenhagen, M.; Maccarrone, G.; Birg, I. N.; Jacob, A.; Uhr, M.; Holsboer, F.; Turck, C. W.: Analysis of cerebrospinal fluid of depressed patients
234
Rothermundt, M.; Peters, M.; Ponath, G.; Erfurth, A.; Wiesmann, M.; Missler, U.; Rudolf, S.; Kirchner, H.; Arolt, V.: Treatment response in major depression is correlated with an increased concentration of the neuroplasticity marker S100B
240
Rupprecht, R.; Lancel, M.; Friess, E.; Ströhle, A.; Holsboer, F.; Romeo, E.: GABAergic effects of neuroactive steroids: Modulation of sleep and anxiety
241
Sachse, J.; Härtter, S.; Gründer, G.; Hiemke, C.: Therapeutic drug monitoring of ziprasidone
242
Sand, P.; Dobmeier, M.; Eichhammer, P.; Hajak, G.; Dallinger, P.; Haen, E.: Gender effects in olanzapine metabolism
243
Sasse, J.; Kirchheiner, J.; Sachse, C.; Lorberg, C.; Bauer, M.; Roots, I.; Brockmöller, J.: Frequency of Cyp2D6, 2C9, 2C19 polymorphisms in depressive and schizophrenic patients
244
Schaefer, M.; Schwaiger, M.; Pich, M.; Franke, E.; Uebelhack, R.; van Boemmel, F.; Berg, T.: Interferon-alpha treatment and serotonergic dysfunction
246
Schaub, R.; Mossiaguine, I.; Cascorbi, I.; Mueller-Oerlinghausen, B.; Dettling, M.: IgG- Fcγ- receptor polymorphisms in drug-induced-induced agranulocytosis
252
254
Schiffelholz, T.; Lancel, M.; Holsboer, F.: The youth hormone DHEA: A benefit for pathologic sleep alterations?
256
Schlösser, R.; Gesierich, T.; Kaufmann, B.; Scherb, C.; Vucurevic, G.; Hunsche, S.; Stoeter, P.: Effective connectivity and pharmacological modulation in schizophrenia
257
Schmidt, L. G.; Degner, D.; Grohmann, R.; Kropp, S.; Bender, S.; Engel, R. R.; Rüther, E.: Severe adverse drug reactions of antidepressants: Results of the German Multicenter Drug Surveillance Program AMSP
259
Schmitt, G. J. E.; Frodl, T.; Dresel, S.; Möller, H. J.; Meisenzahl, E. M.: Striatal dopaminergic synapses In drug-naive versus haloperidol-treated schizophrenic patients
261
Schneider, F.; Burtscheidt, W.; Priebe, M.; Shah, N. J.; Gaebel, W.; Zilles, K.: Alcohol-craving: Therapeutic effects using fMRI
262
Schneider, F.; Habel, U.; Klein, M.; Kellermann, T.; Stoecker, T.; Braus, D.; Schmitt, A.; Schlösser, R.; Smesny, S.; Wagner, M.; Frommann, I.; Kircher, T.; Rapp, A.; Meisenzahl, E. M.; Ufer, S.; Ruhrmann, S.; Müller, M. J.; Shah, N. J.; Sauer, H.; Henn, F. A.; Gaebel, W.: A longitudinal multi-center fMRI study of cognition and emotion in first-episode schizophrenia patients
266
Schubert, M. I.; Droste, S.; Kalisch, R.; Holsboer, F.; Reul, J. H. M. H.; Auer, D. P.: Acute effects of corticosterone on BOLD signal: A pharmacological fMRI study in rats at 7 tesla
269
Schuld, A.; Uhr, M.; Yassouridis, A.; Pollmächer, T.: Influence of sleep deprivation on plasma ghrelin levels in healthy subjects
270
Schüssler, P.; Uhr, M.; Weikel, J. C.; Schmid, D. A.; Held, K.; Mathias, S.; Ising, M.; Steiger, A.: Nocturnal ghrelin levels in normal controls – effects of gender
272
274
275
Sillaber, I.; Ohl, F.; Bartl, C.; Panhuysen, M.; Henniger, M. S. H.; Holsboer, F.: Inbred mouse strains as models for the detection of genes relevant for the effects of antidepressants
276
Sperner-Unterweger, B.; Kohl, C.; Meraner, V.; Holzner, B.; Bodner, T.; Kemmler, G.: Psychopharmacological treatment in cancer patients – Interactions between biological and psychological variables?
277
Spießl, H.; Dobmeier, M.; Ostermeier, C. P.; Klein, H. E.: Subjective response to psychotropic drugs in psychiatric in-patients
279
Sterr, A.; Padberg, F.; Mergl, R.; Amann, B.; Mulert, C.; Juckel, G.; Grunze, H.; Hegerl, U.; Pogarell, O.: EEG abnormalities associated with antidepressant treatment: A comparison of mirtazapine, citalopram, venlafaxine, reboxetine and amitriptyline
286
Teipel, S. J.; Pruessner, J. C.; Graz, C.; Bokde, A. L. W.; Leinsinger, G.; Faltraco, F.; Evans, A. C.; Möller, H. J.; Hampel, H.: Rates of amygdala and hippocampus atrophy in Alzheimer’s disease (AD) – Correlations with cognitive decline
287
Theisen, F. M.; Gebhardt, S.; Haberhausen, M.; Krieg, J. C.; Heinzel-Gutenbrunner, M.; Martin, M.; Remschmidt, H.; Hebebrand, J.: Genetic aspects of antipsychotic induced body weight change
289
Thürauf, N.; Lunkenheimer, J.; Sperling, W.; Bleich, S.; Wiltfang, J.; Plodeck, V.; Wuttke, H.; Rau, T.; Eschenhagen, T.; Kornhuber, J.: CYP2D6-Genotyping in clinical practice: Impact of Genotyp on serum concentrations of psychiatric relevant CYP2D6-substrates
290
Thum, A.; Giesler, M.; Spernal, J.; Holsboer-Trachsler, E.; Krieg, J. C.; Hemmeter, U.: Short and long term effects of mirtazapine and venlafaxine on sleep-EEG in patients with major depression
292
Trenkwalder, C.; Schindehütte, J.; Baier, C.: Restaurative therapy for Parkinson’s disease
293
Tucha, O.; Putzhammer, A.; Aschenbrenner, S.; Eichhammer, P.; Sartor, H.; Klein, H. E.; Lange, K. W.: The impact of tricyclic antidepressants and selective serotonin re-uptake inhibitors on handwriting movements of patients with depression
294
Ufer, S.; Frodl, T.; Kraft, E.; Wiesmüller, M.; Brückmann, H.; Möller, H. J.; Meisenzahl, E. M.: Differences in cortical activation by a working memory task after substitution of atypical neuroleptics
299
van Calker, D.; Willmroth, F.: Mechanism of action of mood stabilizers
300
Vedder, H.; Reckemeyer, I.; Hemmer, B.; Krieg, J. C.: Cytoimmunological changes and treatment response in major depression
303
304
Wagner, T.; Krampe, H.; Stawicki, S.; Reinhold, J.; Jahn, H.; Mahlke, K.; Galwas, C.; Barth, U.; Aust, C.; Kröner-Herwig, B.; Brunner, E.; Poser, W.; Henn, F. A.; Rüther, E.; Ehrenreich, H.: The course of psychiatric comorbidity in chronic alcoholics and its impact on abstinence during 4-year follow-up of integrated outpatient treatment
307
Wehrle, R.; Czisch, M.; Wetter, T. C.; Kaufmann, C.; Holsboer, F.; Auer, D. P.; Pollmächer, T.: Different brain reactivity during phasic and tonic REM sleep: A simultaneous FMRI and EEG study
308
Weikel, J. C.; Held, K.; Wichniak, A.; Ising, M.; Schmid, D. A.; Mathias, S.; Uhr, M.; Steiger, A.: Ghrelin promotes slow-wave sleep in man
310
Weller, L.; Faltraco, F.; Heimberg, E.; Teipel, S.; Bondy, B.; Ackenheil, M.; Möller, H. J.; Hampel, H.: Polymorphisms in the microtubuli associated protein tau and Alzheimer’s disease
311
Wetter, T. C.; Wehrle, R.; Kaufmann, C.; Auer, D. P.; Holsboer, F.; Pollmächer, T.; Czisch, M.: Processing of acoustic stimuli during NREM sleep: Results from a simultaneous fMRI and EEG study
314
Wiltfang, J.; Lewczuk, P.; Maler, M.; Smirnov, A.; Kornhuber, J.: Neurochemical early and differential diagnosis of Alzheimer’s dementia
315
Winkelmann, J.; Lichtner, P.; Strom, T. M.; Trenkwalder, C.; Meitinger, T.; Müller-Myhsok, B.: Evidence for genetic heterogeneity in Restless Legs Syndrome
318
321
Wolf, K.; Mass, R.; Kiefer, F.; Eckert, K.; Weinhold, N.; Wiedemann, K.; Naber, D.: The influence of olanzapine on facial expression of emotions in schizophrenia – An improved facial EMG study
324
Wrase, J.; Klein, S.; Hermann, D.; Gruesser, S. M.; Flor, H.; Braus, D. F.; Mann, K.; Heinz, A.: Relapse and gender specific activation of the striatum in alcohol dependent patients
325
Wurst, F. M.; Bechtel, G.; Forster, S.; Wolfersdorf, M.; Huber, P.; Scholer, A.; Pridzun, L.; Alt, A.; Seidl, S.; Dierkes, J.; Dammann, G.: Leptin levels of alcohol abstainers and detoxification patients are not different
326
Wurst, F. M.; Wiesbeck, G.; Forster, S.; Bechtel, G.; Wolfersdorf, M.; Huber, P.; Alexson, S.; Gilg, T.; Jachau, K.; Varga, A.; Alling, C.; Skipper, G.; Pragst, F.; Auwärter, A.; Weinmann, W.: Further significance for the diagnostic and therapeutic usefulness of the non oxidative direct ethanol metabolites ethyl glucuronide (EtG), fatty acid ethyl esters (FAEEs) and phosphatidyl ethanol (PEth) in comparison to traditional markers
327
Yacubian, J.; Castro, C. C.; Ometto, M.; Barbosa, E.; Camargo, C. P.; Tavares Jr, H.; Cerri, G. G.; Gattaz, W. F.: Relationship between 31P-NMR spectroscopy and neuropsychological performance in schizophrenia
332
Zill, P.; Baghai, T. C.; de Jonge, S.; Neumeier, K.; Ackenheil, M.; Möller, H. J.; Bondy, B.: Different protein expression levels after antidepressant treatment on EBV cells of depressed patients
335
Zobel, A.; Hoefgen, B.; Schwab, S.; v Widdern, O.; Metten, M.; Maier, W.: CRH1- and GR-gene SNPs and haplotypes: Associations with response to Dex/CRH test and antidepressant treatment?